Meta-Analysis
Copyright ©The Author(s) 2021.
World J Hepatol. Jan 27, 2021; 13(1): 144-150
Published online Jan 27, 2021. doi: 10.4254/wjh.v13.i1.144
Table 1 Difference in the impact of entecavir treatment on the risk of hepatocellular carcinoma in patients with hepatitis B virus-associated cirrhosis in various regions of the world
Ref.
Region
Main genotype
Prevalence ratio
Entecavir administered to HBV cirrhotics patients
Observation period (yr)
Incidence of HCC (%/yr)
Riveiro-Barciela et al[3]Spain (Caucasian)D2%-7%644.61.0
Coffin et al[4]Canada (South)D< 2%253.21.3
Hosaka et al[21]Japan (Tokyo)C< 2%795.01.4
Papatheodoridis et al[14]GreeceA2%-7%693.31.8
Idilman et al[11]TurkeyD2%-7%724.02.2
Arends et al[13]CaucasusD> 8%1553.52.2
Su et al[8]TaiwanC> 8%13154.02.4
Köklü et al[12]TurkeyD2%-7%733.02.7
Wong et al[1]Hong KongC> 8%4825.02.8
Watanabe et al[10]Japan (Ehime)C2%-7%865.02.9
Chen et al[9]TaiwanC> 8%5864.93.1
Chen et al[2]China (Chinese)C> 8%614.03.3
Kim et al[5]KoreaC2%-7%3675.03.6
Choi et al[6]KoreaC2%-7%5104.03.8
Table 2 Difference in the incidence of hepatocellular carcinoma under long-term treatment with entecavir between genotype C and genotype D cirrhotic patients

Incidence of HCC (%/yr)
P value
Genotype C group (n = 8)2.91 ± 0.24 (SE)P < 0.01
Genotype D group (n = 5)1.89 ± 0.28 (SE)P < 0.01
Table 3 Comparison of initial hepatitis B virus deoxyribonucleic acid levels (log10 IU/mL) between genotype C and D cirrhotic patients treated with entecavir
Main genotype
Ref.
Entecavir administered to HBV cirrhotic patientssis
Initial HBV DNA
Average
CSu et al[8]13155.55.61
CWong et al[1]4825.0
CWatanabe et al[10]866.4
CChen et al[9]5865.9
CChen et al[2]615.8
CKim et al[5]3674.6
CChoi et al[6]5106.7
DRiveiro-Barciela et al[3]644.95.46
DCoffin et al[4]256.5
DIdilman et al[11]725.5
DArends et al[13]1555.4
DKöklü et al[12]735.7